Promis Neurosciences Inc (PMN)

$14.52 +2.80 (23.89%)
Market Cap 109.41M
Revenue (ttm) 0.00
Net Income (ttm) -39.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,772,318
Avg Vol 55,950
Day's Range N/A - N/A
Shares Out 8.97M
Stochastic %K 9%
Beta -0.23
Analysts Strong Sell
Price Target $32.17

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophi...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
GTMStox
GTMStox Jul. 28 at 7:59 PM
$PMN Yeah this price movement is trash.
0 · Reply
MadisonRamsey
MadisonRamsey Jul. 28 at 7:53 PM
$PMN $ARQQ $OSCR $ELF $GPUS evidence
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 7:47 PM
$PMN still warrants sell off not much left but still the roadblock
0 · Reply
TA_Kongen
TA_Kongen Jul. 28 at 7:27 PM
$PMN No cigar unfortunately.
0 · Reply
MadisonRamsey
MadisonRamsey Jul. 28 at 7:22 PM
$BWAY $NIPG $PMN $SDOT $MRDN possible
0 · Reply
MrGreenth
MrGreenth Jul. 28 at 7:20 PM
$APUS Anyone else miss them runs on $EGG $CISS $INLF $PMN today?! Make sure not to miss ticker $APUS now📈 Only 450k shares remaining to public on APUS , It's the next big squeeze play Looks like shorts got trapped below and now APUS is about to HALT-UP !! Breaking out! 🚀
1 · Reply
Fruchtworg
Fruchtworg Jul. 28 at 7:19 PM
$PMN the volume today .. shown on stocktwits: an astounding 1.59M so far today .. Avg. Volume 30,571,71
0 · Reply
tonkotsu
tonkotsu Jul. 28 at 7:11 PM
$PMN I bought above my cost basis today, which is rare for me. Bought it early this morning when it dropped to 12.5. All good news. This is still way too cheap! Very little chance the final results will be bad. May be bought up shortly after!
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 6:59 PM
$PMN with today’s presentation at the Webinar ProMIS is the new Sheriff in town for Alzheimer and several other neurological diseases no Aria of 144 Probants and best best results in Plasma pTau217 and CSF MTBR-tau243 just wonder who will takeover this 💎 $PFIZER.NSE $JNJ $BMY https://d1io3yog0oux5.cloudfront.net/_a52bc4a1574a61db158bebe9c6f0d9df/promisneurosciences/db/933/8992/pdf/Confidential+and+Final+-+PRECISE-AD+Interim+Results+Presentation.pdf
0 · Reply
TA_Kongen
TA_Kongen Jul. 28 at 6:48 PM
$PMN One last HOD clear before close? Let's see it.
0 · Reply
Latest News on PMN
ProMIS Neurosciences price target raised to $33 from $20 at Chardan

2026-07-28T14:15:51.000Z - 8 hours ago

ProMIS Neurosciences price target raised to $33 from $20 at Chardan

ProMIS Neurosciences Transcript: Study result

Jul 28, 2026, 8:00 AM EDT - 10 hours ago

ProMIS Neurosciences Transcript: Study result

ProMIS Neurosciences Slides: Study result

Jul 28, 2026, 8:00 AM EDT - 10 hours ago

ProMIS Neurosciences Slides: Study result

ProMIS Neurosciences Press release: Study result

Jul 28, 2026, 8:00 AM EDT - 10 hours ago

ProMIS Neurosciences Press release: Study result

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

2026-07-28T11:30:29.000Z - 10 hours ago

ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim

ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial

2026-07-28T10:20:31.000Z - 11 hours ago

ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

Jul 28, 2026, 6:00 AM EDT - 12 hours ago

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

Jul 27, 2026, 4:00 PM EDT - 1 day ago

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease

ProMIS Neurosciences initiated with a Buy at Chardan

2026-07-27T08:20:12.000Z - 1 day ago

ProMIS Neurosciences initiated with a Buy at Chardan

ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310

2026-07-14T09:35:45.000Z - 14 days ago

ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Jul 14, 2026, 2:30 AM EDT - 14 days ago

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences initiated with a Buy at Roth Capital

2026-07-08T09:25:08.000Z - 20 days ago

ProMIS Neurosciences initiated with a Buy at Roth Capital

ProMIS Neurosciences initiated with a Buy at Roth Capital

2026-07-07T20:10:17.000Z - 21 days ago

ProMIS Neurosciences initiated with a Buy at Roth Capital

ProMIS Neurosciences initiated with an Overweight at Cantor Fitzgerald

2026-06-30T09:30:18.000Z - 4 weeks ago

ProMIS Neurosciences initiated with an Overweight at Cantor Fitzgerald

ProMIS Neurosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 7 weeks ago

ProMIS Neurosciences Transcript: Jefferies Global Healthcare Conference 2026

ProMIS Neurosciences to Participate in Upcoming Conferences in June

May 28, 2026, 10:13 AM EDT - 2 months ago

ProMIS Neurosciences to Participate in Upcoming Conferences in June

ProMIS Neurosciences Transcript: AGM 2026

May 20, 2026, 10:30 AM EDT - 2 months ago

ProMIS Neurosciences Transcript: AGM 2026

ProMIS Neurosciences initiated with a Buy at Brookline

2026-05-20T10:26:02.000Z - 2 months ago

ProMIS Neurosciences initiated with a Buy at Brookline

ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year

2026-05-12T11:26:17.000Z - 2 months ago

ProMIS Neurosciences reports Q1 EPS ($1.26) vs. ($5.27) last year

ProMIS Neurosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

ProMIS Neurosciences Earnings release: Q1 2026

ProMIS Neurosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 2 months ago

ProMIS Neurosciences Quarterly report: Q1 2026

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

May 12, 2026, 6:30 AM EDT - 2 months ago

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Slides: Investor presentation

May 11, 2026, 7:00 AM EDT - 2 months ago

ProMIS Neurosciences Slides: Investor presentation

ProMIS Neurosciences Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 2:30 PM EDT - 3 months ago

ProMIS Neurosciences Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 13, 2026, 7:30 AM EDT - 3 months ago

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

ProMIS Neurosciences Proxy statement: Proxy filing

ProMIS Neurosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 3 months ago

ProMIS Neurosciences Proxy statement: Proxy filing

ProMIS Neurosciences files $200M mixed securities shelf

2026-03-25T21:25:26.000Z - 4 months ago

ProMIS Neurosciences files $200M mixed securities shelf

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Annual report: Q4 2025

ProMIS Neurosciences Earnings release: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Earnings release: Q4 2025

ProMIS Neurosciences Registration statement: Registration filing

Mar 25, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Registration statement: Registration filing

ProMIS Neurosciences files to sell 13.83M common shares for holders

2026-03-18T20:21:15.000Z - 4 months ago

ProMIS Neurosciences files to sell 13.83M common shares for holders

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

Mar 18, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences Registration statement: Registration Filing

Mar 18, 2026, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Registration statement: Registration Filing

ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 9:30 AM EST - 5 months ago

ProMIS Neurosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 6 months ago

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Promis Neurosciences Inc trading resumes

2026-01-30T14:40:46.000Z - 6 months ago

Promis Neurosciences Inc trading resumes

Promis Neurosciences Inc trading halted, volatility trading pause

2026-01-30T14:35:31.000Z - 6 months ago

Promis Neurosciences Inc trading halted, volatility trading pause

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Jan 30, 2026, 8:00 AM EST - 6 months ago

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences exceeds target enrollment in PRECISE-AD

2025-12-18T12:36:07.000Z - 7 months ago

ProMIS Neurosciences exceeds target enrollment in PRECISE-AD

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 18, 2025, 7:30 AM EST - 7 months ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

ProMIS Neurosciences announces publication highlighting PMN310

2025-12-10T12:45:11.000Z - 8 months ago

ProMIS Neurosciences announces publication highlighting PMN310

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 10, 2025, 7:30 AM EST - 8 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

ProMIS Neurosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:25 PM EST - 8 months ago

ProMIS Neurosciences Transcript: Evercore ISI 8th Annual HealthCONx Conference

ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright

2025-12-01T13:50:42.000Z - 8 months ago

ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright

ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s

2025-12-01T12:45:37.000Z - 8 months ago

ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:30 AM EST - 8 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 8 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Promis Neurosciences Inc trading halted, news pending

2025-11-27T00:50:21.000Z - 8 months ago

Promis Neurosciences Inc trading halted, news pending

ProMIS Neurosciences announces 1-for-20 reverse stock split

2025-11-24T13:25:21.000Z - 8 months ago

ProMIS Neurosciences announces 1-for-20 reverse stock split

ProMIS Neurosciences Announces Reverse Stock Split

Nov 24, 2025, 8:00 AM EST - 8 months ago

ProMIS Neurosciences Announces Reverse Stock Split

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 12, 2025, 7:00 AM EST - 9 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

ProMIS Neurosciences Earnings release: Q3 2025

ProMIS Neurosciences Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 9 months ago

ProMIS Neurosciences Quarterly report: Q3 2025

ProMIS Neurosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 11:00 AM EST - 9 months ago

ProMIS Neurosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 4:05 PM EST - 9 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Oct 22, 2025, 7:30 AM EDT - 9 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

ProMIS Neurosciences Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 10 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Oct 3, 2025, 8:00 AM EDT - 10 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 11 months ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:30 PM EDT - 11 months ago

ProMIS Neurosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

ProMIS Neurosciences Registration statement: Registration Filing

Sep 4, 2025, 8:00 AM EDT - 11 months ago

ProMIS Neurosciences Registration statement: Registration Filing

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Sep 3, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

ProMIS Neurosciences Registration statement: Registration Filing

Aug 13, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Registration statement: Registration Filing

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

ProMIS Neurosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q2 2025

ProMIS Neurosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Quarterly report: Q2 2025

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 29, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

ProMIS Neurosciences Announces Private Placement Financing

Jul 28, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jul 21, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Quarterly report: Q1 2025

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Quarterly report: Q1 2025

ProMIS Neurosciences Earnings release: Q1 2025

May 12, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q1 2025

ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Annual report: Q4 2024

ProMIS Neurosciences Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Earnings release: Q4 2024

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 24, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 13, 2025, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Mar 11, 2025, 7:30 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:30 PM EST - 1 year ago

ProMIS Neurosciences Transcript: Guggenheim SMID Cap Biotech Conference

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

ProMIS Neurosciences Quarterly report: Q3 2024

ProMIS Neurosciences Earnings release: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

ProMIS Neurosciences Earnings release: Q3 2024

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 12, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Sep 9, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences Registration statement: Registration Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Registration statement: Registration Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Aug 29, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Quarterly report: Q2 2024

ProMIS Neurosciences Earnings release: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q2 2024

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 30, 2024, 8:30 AM EDT - 2 years ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:35 AM EDT - 2 years ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Jul 26, 2024, 8:30 AM EDT - 2 years ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024, 4:01 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Quarterly report: Q1 2024

May 13, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Quarterly report: Q1 2024

ProMIS Neurosciences Earnings release: Q1 2024

May 13, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q1 2024

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 30, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Proxy statement: Proxy Filing

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 9, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 4, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 4:15 PM EDT - 2 years ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Earnings release: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Earnings release: Q4 2023

ProMIS Neurosciences Annual report: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

ProMIS Neurosciences Annual report: Q4 2023

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences, Inc. Announces Leadership Transition

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

GTMStox
GTMStox Jul. 28 at 7:59 PM
$PMN Yeah this price movement is trash.
0 · Reply
MadisonRamsey
MadisonRamsey Jul. 28 at 7:53 PM
$PMN $ARQQ $OSCR $ELF $GPUS evidence
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 7:47 PM
$PMN still warrants sell off not much left but still the roadblock
0 · Reply
TA_Kongen
TA_Kongen Jul. 28 at 7:27 PM
$PMN No cigar unfortunately.
0 · Reply
MadisonRamsey
MadisonRamsey Jul. 28 at 7:22 PM
$BWAY $NIPG $PMN $SDOT $MRDN possible
0 · Reply
MrGreenth
MrGreenth Jul. 28 at 7:20 PM
$APUS Anyone else miss them runs on $EGG $CISS $INLF $PMN today?! Make sure not to miss ticker $APUS now📈 Only 450k shares remaining to public on APUS , It's the next big squeeze play Looks like shorts got trapped below and now APUS is about to HALT-UP !! Breaking out! 🚀
1 · Reply
Fruchtworg
Fruchtworg Jul. 28 at 7:19 PM
$PMN the volume today .. shown on stocktwits: an astounding 1.59M so far today .. Avg. Volume 30,571,71
0 · Reply
tonkotsu
tonkotsu Jul. 28 at 7:11 PM
$PMN I bought above my cost basis today, which is rare for me. Bought it early this morning when it dropped to 12.5. All good news. This is still way too cheap! Very little chance the final results will be bad. May be bought up shortly after!
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 6:59 PM
$PMN with today’s presentation at the Webinar ProMIS is the new Sheriff in town for Alzheimer and several other neurological diseases no Aria of 144 Probants and best best results in Plasma pTau217 and CSF MTBR-tau243 just wonder who will takeover this 💎 $PFIZER.NSE $JNJ $BMY https://d1io3yog0oux5.cloudfront.net/_a52bc4a1574a61db158bebe9c6f0d9df/promisneurosciences/db/933/8992/pdf/Confidential+and+Final+-+PRECISE-AD+Interim+Results+Presentation.pdf
0 · Reply
TA_Kongen
TA_Kongen Jul. 28 at 6:48 PM
$PMN One last HOD clear before close? Let's see it.
0 · Reply
healthcareguru
healthcareguru Jul. 28 at 6:45 PM
$PMN sooo many suckers…you were warned. See you back at $12 soon. 👎 $XBI $XLV
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 6:29 PM
Top Gainers PT2 $STFS $OPK $INLF $TRIB $PMN
1 · Reply
Fruchtworg
Fruchtworg Jul. 28 at 5:09 PM
$PMN soo.. Biogen earnings call tomorrow if my information is correct, before the market opens .. and an earnings call where i am sure analysts will follow up on this ! 🕵️
0 · Reply
topstockalerts
topstockalerts Jul. 28 at 5:09 PM
Midday Top Gainers $EGG $DFNS $CISS $INLF $PMN
0 · Reply
Dopamineaddict
Dopamineaddict Jul. 28 at 5:04 PM
$ANVS Could we see Annovis use the $PMN playbook, by disclosing blinded biomarker data at the 3 month mark? That PMN data looks promising. Is Alzheimer’s on the ropes?
2 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS Jul. 28 at 4:49 PM
$PMN 2/3 of patients are on the drug, the other on the placebo. 65% had their biomarker reduced... what is it that the market doesn't understand? I think a partnership will be announced sooner or later.
0 · Reply
Fruchtworg
Fruchtworg Jul. 28 at 4:40 PM
$PMN hahahhaha 🙈
0 · Reply
healthcareguru
healthcareguru Jul. 28 at 4:32 PM
$PMN short this piggy all day…nonsense partial Ph1 update while they’re bleeding cash…get ready for more dilution. 👎 $XBI $XLV
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 4:27 PM
$PMN either $LLY , $BIIB or $RHHBY will have to buy ProMIS otherwise each of them is going to lose at least $7-10 bn of the fast growing Alzheimer market. Presentation of today https://d1io3yog0oux5.cloudfront.net/_a52bc4a1574a61db158bebe9c6f0d9df/promisneurosciences/db/933/8992/pdf/Confidential+and+Final+-+PRECISE-AD+Interim+Results+Presentation.pdf
1 · Reply
STACKD0E
STACKD0E Jul. 28 at 4:10 PM
$PMN 👁️
0 · Reply
GoforProMIS
GoforProMIS Jul. 28 at 4:10 PM
$PMN today presentation and take a look at the Webinar this morning with 2 KOL participants Dr. Will Mantyh and Dr. Michael Weiner they said both PMN310 is a gamechanger with no ARIA and even results of for Plasma pTau217 and CSF MTBR-tau243 https://lifescievents.com/event/it38tlq/
0 · Reply
ajmrtxl
ajmrtxl Jul. 28 at 4:05 PM
$PMN 's latest squeeze play
0 · Reply